890808 | 22:0 Trehalose
D-(+)-trehalose 6,6'-dibehenate
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
22:0 Trehalose
D-(+)-trehalose 6,6'-dibehenate
Incorporation of the glycolipid trehalose 6,6'-dibehenate (TDB) into cationic liposomes composed of the quaternary ammonium compound dimethyldioctadecylammonium (DDA) produce an adjuvant system which induces a powerful cell-mediated immune response and a strong antibody response, desirable for a high number of disease targets.
CAS Registry Number is a Registered Trademark of the American Chemical Society
6,6'-didocosanoyl-α,α'-trehalose
Powered by BiozTeng X, Tian M, Li J, Tan S, Yuan X, Yu Q, Jing Y, Zhang Z, Yue T, Zhou L, Fan X. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine. Hum Vaccin Immunother. 2015;11(6):1456-64. doi: 10.1080/21645515.2015.1037057. PMID: 25905680; PMCID: PMC4514263.
PubMed ID: 25905680Rose F, Wern JE, Ingvarsson PT, van de Weert M, Andersen P, Follmann F, Foged C. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach. J Control Release. 2015 Jul 28;210:48-57. doi: 10.1016/j.jconrel.2015.05.004. Epub 2015 May 6. PMID: 25957906.
PubMed ID: 25957906Derrick SC, Yabe I, Morris S, Cowley S. Induction of Unconventional T Cells by a Mutant Mycobacterium bovis BCG Strain Formulated in Cationic Liposomes Correlates with Protection against Mycobacterium tuberculosis Infections of Immunocompromised Mice. Clin Vaccine Immunol. 2016 Jul 5;23(7):638-47. doi: 10.1128/CVI.00232-16. PMID: 27226281; PMCID: PMC4933783.
PubMed ID: 27226281Larrouy-Maumus G, Layre E, Clark S, Prandi J, Rayner E, Lepore M, de Libero G, Williams A, Puzo G, Gilleron M. Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis. Vaccine. 2017 Mar 7;35(10):1395-1402. doi: 10.1016/j.vaccine.2017.01.079. Epub 2017 Feb 9. PMID: 28190740.
PubMed ID: 28190740Hansen M, Peltier J, Killy B, Amin B, Bodendorfer B, Härtlova A, Uebel S, Bosmann M, Hofmann J, Büttner C, Ekici AB, Kuttke M, Franzyk H, Foged C, Beer-Hammer S, Schabbauer G, Trost M, Lang R. Macrophage phosphoproteome analysis reveals MINCLE-dependent and -independent mycobacterial cord factor signaling. Mol Cell Proteomics. 2019 Jan 11. pii: mcp.RA118.000929. doi: 10.1074/mcp.RA118.000929. [Epub ahead of print]
PubMed ID: 30635358Fomsgaard, A., Karlsson, I., Gram, G., Schou, C., Tang, S., Bang, P., Kromann, I., Andersen, P., Andreasen, L.V. (2011) Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine. 29:7067-74.
PubMed ID: 21767590Nordly, P., Agger, E.M., Andersen, P., Nielsen, H.M., Foged, C. (2011) Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo. Pharm Res. 28:553-62.
PubMed ID: 21042837Gram, G.J., Karlsson, I., Agger, E.M., Andersen, P., Fomsgaard, A. (2009) A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS One. 4:e6950.
PubMed ID: 19759892Davidsen, J., Rosenkrands, I., Christensen, D., Vangala, A., Kirby, D., Perrie, Y., Agger, E.M., Andersen, P. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta. 1718:22-31.
PubMed ID: 16321607- Certificate of Analysis (Lot No. 890808P-25MG-A-017 and 6351PJA017)
- Certificate of Analysis (Lot No. 890808P-5MG-A-017 and 6351PHA017)
- Certificate of Analysis (Lot No. 890808P-25MG-B-017 and 6351PJB017)
- Certificate of Analysis (Lot No. 890808P-5MG-B-017 and 6351PHB017)
- Certificate of Analysis (Lot No. 890808P-5MG-C-017 and 6351PHC017)
- Certificate of Analysis (Lot No. 890808P-25MG-C-017 and 6351PJC017)
- Certificate of Analysis (Lot No. 890808P-5MG-D-017 and 6351PHD017)
- Certificate of Analysis (Lot No. 890808P-5MG-E-017 and 6351PHE017)
- Certificate of Analysis (Lot No. 890808P-5MG-F-017 and 6351PHF017)
- Certificate of Analysis (Lot No. 890808P-25MG-D-017 and 6351PJD017)
- Certificate of Analysis (Lot No. 890808P-25MG-A-018 and 6351PJA018)
- Certificate of Analysis (Lot No. 890808P-5MG-A-019 and 6351PHA019)
- Certificate of Analysis (Lot No. 890808P-25MG-A-019 and 6351PJA019)
- Certificate of Analysis (Lot No. 890808P-25MG-B-018 and 6351PJB018)
- Certificate of Analysis (Lot No. 890808P-5MG-B-019 and 6351PHB019)
- Certificate of Analysis (Lot No. 890808P-5MG-C-019 and 6351PHC019)
